Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Location
Florham Park, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 250% % 93%
Debt-to-equity 76% % -79%
Return On Equity -206% % 74%
Return On Assets -108% % 34%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,240,134 shares -90%
Common Stock, Shares, Outstanding 3,192,040 shares -92%
Entity Public Float $89,095,619 USD 371%
Common Stock, Value, Issued $32 USD -92%
Weighted Average Number of Shares Outstanding, Basic 3,162,040 shares 141%
Weighted Average Number of Shares Outstanding, Diluted 3,162,040 shares 138%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $14,549,429 USD -47%
General and Administrative Expense $15,484,613 USD -35%
Costs and Expenses $30,034,042 USD -42%
Operating Income (Loss) $30,034,042 USD 42%
Nonoperating Income (Expense) $11,248,852 USD 696%
Net Income (Loss) Attributable to Parent $18,851,190 USD 62%
Earnings Per Share, Basic 6 USD/shares 87%
Earnings Per Share, Diluted 12 USD/shares 88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,554,289 USD -63%
Assets, Current $13,621,698 USD -62%
Property, Plant and Equipment, Net $595,271 USD -35%
Operating Lease, Right-of-Use Asset $380,841 USD -16%
Other Assets, Noncurrent $29,780 USD 0%
Assets $14,627,590 USD -61%
Accounts Payable, Current $4,105,000 USD -27%
Liabilities, Current $4,912,366 USD -76%
Operating Lease, Liability, Noncurrent $335,895 USD -22%
Liabilities $5,248,261 USD -75%
Retained Earnings (Accumulated Deficit) $263,838,280 USD -7.7%
Stockholders' Equity Attributable to Parent $7,997,306 USD -47%
Liabilities and Equity $14,627,590 USD -61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,383,434 USD 30%
Net Cash Provided by (Used in) Financing Activities $43,849,467 USD
Net Cash Provided by (Used in) Investing Activities $21,633 USD
Common Stock, Shares Authorized 170,000,000 shares 0%
Common Stock, Shares, Issued 3,192,040 shares -92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,383,434 USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12,554,289 USD -63%
Deferred Tax Assets, Valuation Allowance $107,485,240 USD 22%
Deferred Tax Assets, Gross $107,608,426 USD 22%
Operating Lease, Liability $433,000 USD -16%
Payments to Acquire Property, Plant, and Equipment $21,633 USD
Lessee, Operating Lease, Liability, to be Paid $548,000 USD -21%
Operating Lease, Liability, Current $96,034 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Two $153,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year One $150,000 USD 2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $115,000 USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year Three $156,000 USD 2%
Preferred Stock, Shares Issued 36 shares
Preferred Stock, Shares Authorized 1,225 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four $155,000 USD 1.3%
Additional Paid in Capital $271,314,776 USD 10%
Preferred Stock, Shares Outstanding 36 shares
Depreciation, Depletion and Amortization $56,295 USD -36%
Deferred Tax Assets, Net of Valuation Allowance $107,485,240 USD 22%